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Lassa virus, the cause of Lassa fever in humans, is endemic to West Africa. Treatment of Lassa fever is primarily
supportive, although ribavirin has shown limited efficacy if
administered early during infection. We tested favipiravir in
Lassa virus–viremic macaques and found that 300 mg/kg
daily for 2 weeks successfully treated infection.

L

assa virus (LASV; family Arenaviridae, genus Mammarenavirus) is the etiologic agent of the severe
hemorrhagic disease Lassa fever. Annually, ≈300,000
persons become infected with LASV, 20% of which experience life-threatening clinical manifestations including edema, hemorrhage, and multiorgan failure, resulting
in an estimated 5,000 deaths (1). Most human infections
are acquired from the natural rodent reservoir, the multimammate rat (Mastomys natalensis). Human-to-human
transmission, mostly nosocomial, occurs (1). LASV has a
relatively well-defined region of endemicity exclusive to
West Africa. Incidence of LASV infections is highest in
Nigeria, Sierra Leone, Liberia, and Guinea, although sporadic cases and moderate outbreaks of Lassa fever have
been documented in many other West Africa nations (online Technical Appendix Figure 1, https://wwwnc.cdc.gov/
EID/article/24/9/18-0233-Techapp1.pdf) (2). Over several
decades, importation of Lassa fever into Europe, Asia, and
the Americas has increased (2).
Treatment of Lassa fever is largely supportive, although
ribavirin is used off label, despite side effects and limited
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efficacy data (3). Recently, the antiviral favipiravir (T-705;
6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has gained attention as a broad-spectrum antiviral drug against RNA viruses (4) including LASV; initial studies using small animal
models have been conducted (5,6). We assessed the antiviral
efficacy of favipiravir in LASV-infected cynomolgus macaques; this animal model reliably recapitulates several hallmarks of Lassa fever infection in humans (7).
The Study
We randomly divided 8 female cynomolgus macaques
(Macaca fascicularis) into 2 groups of 4 each (treatment
and control) and injected each animal intramuscularly with
a lethal dose of LASV, strain Josiah (1 × 104 50% tissue
culture infective dose [TCID50]) (Table). Treatment began
at 4 days postinfection (dpi), 1 day after the onset of viremia (7). The initial treatment (300 mg/kg favipiravir) was
administered intravenously; subsequent treatments (300
mg/kg favipiravir every 24 h for 13 d) were administered
subcutaneously. The dosage was based on the successful treatment of Lassa fever in guinea pigs (5). To avoid
the confounding effects of ribavirin, we did not give it in
combination. LASV-infected control animals received an
equivalent volume of vehicle by the same route and schedule. Animals were assessed twice daily; physical examinations, including hematologic, blood chemistry, and virologic assessments, were conducted regularly.
Reduced activity and appetite, probably resulting from
being anesthetized daily, was noted early in animals in both
groups (Figure 1, panel A). At 6 dpi (2 d after treatment
began), clinical scores for 3 of 4 animals in the treatment
group plateaued and remained consistent for the remainder
of the study. Although the score for the remaining animal
was higher, all favipiravir-treated animals survived LASV
challenge (p<0.01; Figure 1, panel B). In contrast, clinical
scores for the control group increased dramatically after 8
dpi; all control animals displayed anorexia, hunched posture, piloerection, and lethargy (Figure 1, panel A). The
control animals reached the humane endpoint and were euthanized on 10, 11, and 12 dpi (Figure 1, panel B).
Although we detected viral RNA by quantitative PCR as
early as 3 dpi (online Technical Appendix Figure 2, panel A),
at no time was infectious LASV isolated from blood (Figure
1, panel C) or postmortem tissue samples (data not shown)
from animals in the favipiravir group. However, in the
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Table. Study design for treatment of Lassa virus infection in cynomolgus macaques*
Study, no.
animals
Treatment
Frequency†
Dose, mg/kg
Loading dose, mg/kg Total daily dose, mg/kg
First
4
Placebo
Every 24 h
Volume equivalent
Volume equivalent
Volume equivalent
4
Favipiravir
Every 24 h
300
300
300
Second
4
Placebo
Every 8 h
Volume equivalent.
Volume equivalent
Volume equivalent
4
Favipiravir
Every 8 h
50
300
150

Survived/total,
no.
0/4
4/4
0/4
0/4

*All animals were challenged with a previously determined lethal dose of 104 50% tissue culture infective dose of Lassa virus (strain Josiah) via
intramuscular injection. At day 4 after infection, a time coinciding with the earliest onset of detectable viremia, treatment with placebo or drug was initiated
by intravenous injection of the loading dose followed by daily (days 5–17) subcutaneous dosing. Animals were examined daily for clinical signs of disease,
and samples were taken for hematologic, blood chemistry, and virologic analyses at 12 times throughout the study, beginning on the day of virus
challenge and ending on day 56 after infection.
†For 14 d.

control animals, increased liver enzyme levels were detected
at 6 dpi, coinciding with infectious LASV (Figure 1, panels D, E). One animal in the favipiravir group demonstrated

moderately increased levels of alanine aminotransferase and
aspartate aminotransferase at 6–12 dpi, which resolved after treatment cessation. In the control animals, albumin and
Figure 1. Effect of daily
favipiravir treatments on
morbidity and mortality rates,
viral loads, and selected blood
chemistry and hematology
values during the course of the
efficacy study in cynomolgus
macaques challenged with
104 TCID50 of Lassa virus.
Groups of 4 animals each
were given 300 mg/kg/d of
favipiravir or placebo for 14
consecutive days, beginning
on day 4 postinfection. A)
Daily clinical scores (dotted
line indicates euthanasia
score of 35). B) Survival
curve (*p<0.01 compared
with placebo-treated animals
by the Mantel-Cox log-rank
test). C) Viremia as assessed
by TCID50 assay. D) Alanine
aminotransferase levels. E)
Aspartate aminotransferase
levels. F) Albumin levels. G)
Total protein levels. H) Platelet
levels. TCID50, 50% tissue
culture infective dose.
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Figure 2. Histologic and in situ
hybridization analyses of livers
from cynomolgus macaques
infected with Lassa virus (LASV) (1
× 104 50% tissue culture infective
dose [TCID50]) and treated 1 time
daily with favipiravir (treated)
or vehicle only (control). A–B)
Histologic analyses. A) Control,
showing multifocal neutrophilic
infiltrates with hepatocyte
necrosis and degeneration
(original magnification ×40).
Inset shows hepatocyte necrosis
(original magnification ×400).
B) Treated, showing essentially
healthy hepatic tissue (original
magnification ×40). Inset shows
healthy hepatic tissue (original
magnification ×400). C–D) In situ
hybridization analyses. C) Control,
showing multifocal and coalescing
viral RNA detected within
hepatocytes (original magnification
×100). D) Treated, showing no
viral RNA detected (original
magnification ×100).

total protein levels decreased dramatically throughout LASV
infection; in the favipiravir-treated animals, these levels displayed a more moderate decrease before returning toward
reference levels (Figure 1, panels F, G).
Hematologic profiles were less uniform between the
2 groups, although we observed several abnormalities previously associated with LASV infection (online Technical Appendix Figure 3). After an initial increase, platelet
counts in the control animals consistently decreased until
euthanasia. In 2 of the favipiravir-treated animals, a similar
increase was noted initially; however, a marked decrease
occurred at 6 dpi (Figure 1, panel H). Platelet levels rebounded by 9 dpi and continued to increase. In addition,
all 4 favipiravir-treated animals had lipemia (>301 mg/dL)
during the treatment phase of the study (4–18 dpi).
Histopathologic examination of livers from control
animals demonstrated hepatitis with neutrophil invasion
and substantial steatosis, consistent with Lassa fever in
this model (Figure 2, panel A) (7). In contrast, livers from
favipiravir-treated animals showed no abnormalities (Figure 2, panel B). In situ hybridization detected LASV RNA
within hepatocytes of control animals but not treated animals (Figure 2, panels C, D).
Conclusions
Over the past 3 years, total numbers of Lassa fever cases
and case-fatality rates among humans have increased (8).
The current Lassa fever outbreak in Nigeria and Benin continues to show large numbers of Lassa fever cases and case1698

fatality rates >30% (8), again highlighting the lack of available treatments. Furthermore, the recent person-to-person
transmission of LASV in Germany (9) serves as a reminder
that Lassa fever is of global health concern.
Lassa fever patients are largely managed by supportive
care in combination with ribavirin (3). Experimental efficacy of ribavirin was initially tested in a Lassa fever rhesus
macaque model in which intramuscular injections 3 times
daily for 14 days improved survival rates (10). In clinical
trials in Sierra Leone, both oral and intravenous ribavirin
increased survival rates of Lassa fever patients (11). Oral
dosing of ribavirin has since remained the standard of
treatment for Lassa fever, despite unproven efficacy from
clinical studies (3,12). Moreover, side effects of ribavirin
therapy have resulted in noncompliance (12).
The successful daily administration of favipiravir to macaques at an elevated dosing regimen of 300 mg/kg/d may
partially explain the transient thrombocytopenia, elevated
liver enzyme levels, and lipemia found in this study. Experimentally, favipiravir is a well-known broad-spectrum antiviral drug with in vitro inhibitory activity against a multitude
of RNA viruses (4). In Japan, favipiravir is approved for influenza treatment; in the United States, phase 3 clinical trials
for the same indication have been completed (4). During the
West Africa Ebola outbreak, favipiravir was administered to
humans on an emergency basis under a different dosing regimen, but effectiveness was limited (13). We therefore designed a second study that more closely followed the dosing
in the Ebola trial (50 mg/kg every 8 h) (13). However, this
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multiple dose per day format failed to protect cynomolgus
macaques from Lassa fever and did not alter disease progression (Table; online Technical Appendix Figure 1, panel B,
and Figure 4, panels A–D). Of note, the high-dose favipiravir therapy in macaques successfully abated the pathophysiologic parameters associated with LASV infection, resulting
in survival. These results suggest that low doses of favipiravir have limited therapeutic effect, whereas higher doses are
therapeutic and will improve clinical outcomes.
Favipiravir was recently administered in combination
with ribavirin to successfully treat Lassa fever in 2 human
patients. Although it is not possible to determine how effective favipiravir was in controlling these 2 cases, administration reduced viremia in both patients (9). Combination
therapy with favipiravir and ribavirin in immunocompromised mice with LASV infection showed efficacy with
suboptimal doses of each drug (6). The synergistic effect
of the 2 compounds is also supported by several other studies in rodents (14). Recently, human monoclonal antibody
therapy protected cynomolgus macaques from LASV infection (15). Combination therapy with favipiravir may be
a future therapeutic strategy (15). On the basis of our findings, improved favipiravir tolerability in humans (4), availability of an oral formulation, and its advanced preclinical
status (according to the US Food and Drug Administration), we recommend that favipiravir enter clinical trials as
a treatment for Lassa fever.
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